title: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer.
abstract: BACKGROUND
  The deregulation of microRNAs in both tumours and blood has led to the search for microRNAs to indicate the presence of cancer and predict prognosis. We hypothesize the deregulation of miR-200c/miR-141 in the whole blood can identify breast cancer (BC), and could be developed into a prognostic signature.
  
  
  METHODS
  The expression of miR-200c and miR-141 were examined in bloods (57 stage I-IV BC patients and 20 age-matched controls) by quantitative reverse-transcription PCR. The associations of circulating microRNAs with clinic and pathological characteristics were analysed. Their effects on survival were analysed by the Kaplan-Meier method and Cox regressions.
  
  
  RESULTS
  MiR-200c was down regulated (P < 0.0001) in the blood of BC patients, yielded an area under the ROC curve of 0.79 (90% sensitivity, 70.2% specificity) in discriminating BC from controls. Circulating miR-141 was not discriminating. MiR-200c and miR-141 in the blood of BC patients were inversely correlated (P = 0.019). The miR-200c levels were numerically higher in stage IV and tumours with lower MIB-1. MiR-141 was significantly higher in the blood of patients with stage I-III, lymph node metastasis, and HER2 negative tumours. High blood expression of miR-200c and/or low expression of miR-141 was associated with unfavourable overall survival (hazard ratio, 3.89; [95% CI: 1.28-11.85]) and progression-free survival (3.79 [1.41-10.16]) independent of age, stage and hormonal receptors.
  
  
  CONCLUSIONS
  Circulating miR-200c and miR-141 were deregulated in BC comparing with controls. Furthermore, miR-200c and miR-141 were independent prognostic factors and associated with distinct outcomes of BC patients.
authors.affiliation: Medical Oncology Department, La Coruña University Hospital (CHUAC), Servicio Galego de Saúde (SERGAS), As Xubias, 84 PC 15006, La Coruña, Spain. Silvia.Antolin.Novoa@sergas.es.
authors.forename: Silvia
authors.initials: S
authors.lastname: Antolín
authors.affiliation: Medical Oncology Department, La Coruña University Hospital (CHUAC), Servicio Galego de Saúde (SERGAS), As Xubias, 84 PC 15006, La Coruña, Spain. Lourdes.Calvo.Martinez@sergas.es.
authors.forename: Lourdes
authors.initials: L
authors.lastname: Calvo
authors.affiliation: Translational Cancer Research Lab, Biomedical Research Institute (INIBIC), Carretera del Pasaje, s/n. PC 15006, La Coruña, Spain. Moises.Blanco.Calvo@sergas.es.
authors.forename: Moisés
authors.initials: M
authors.lastname: Blanco-Calvo
authors.affiliation: Pathology Department, La Coruña University Hospital (CHUAC), Servicio Galego de Saúde (SERGAS), As Xubias, 84 PC 15006, La Coruña, Spain. Maria.Paz.Santiago.Freijanes@sergas.es.
authors.forename: María Paz
authors.initials: MP
authors.lastname: Santiago
authors.affiliation: Pathology Department, La Coruña University Hospital (CHUAC), Servicio Galego de Saúde (SERGAS), As Xubias, 84 PC 15006, La Coruña, Spain. Maria.Lorenzo.Patino@sergas.es.
authors.forename: María José
authors.initials: MJ
authors.lastname: Lorenzo-Patiño
authors.affiliation: Translational Cancer Research Lab, Biomedical Research Institute (INIBIC), Carretera del Pasaje, s/n. PC 15006, La Coruña, Spain. Maria.del.Mar.Haz.Conde@sergas.es.
authors.forename: Mar
authors.initials: M
authors.lastname: Haz-Conde
authors.affiliation: Translational Cancer Research Lab, Biomedical Research Institute (INIBIC), Carretera del Pasaje, s/n. PC 15006, La Coruña, Spain. Isabel.Santamarina.Cainzos@sergas.es.
authors.forename: Isabel
authors.initials: I
authors.lastname: Santamarina
authors.affiliation: Translational Cancer Research Lab, Biomedical Research Institute (INIBIC), Carretera del Pasaje, s/n. PC 15006, La Coruña, Spain. Angelica.Figueroa.Conde-Valvis@sergas.es.
authors.forename: Angélica
authors.initials: A
authors.lastname: Figueroa
authors.affiliation: Medical Oncology Department, La Coruña University Hospital (CHUAC), Servicio Galego de Saúde (SERGAS), As Xubias, 84 PC 15006, La Coruña, Spain. Luis.M.Anton.Aparicio@sergas.es.|Medicine Department, La Coruña University (UDC), Campus de Oza, s/n; PC 15006, La Coruña, Spain. Luis.M.Anton.Aparicio@sergas.es.
authors.forename: Luis Miguel
authors.initials: LM
authors.lastname: Antón-Aparicio
authors.affiliation: Medical Oncology Department, La Coruña University Hospital (CHUAC), Servicio Galego de Saúde (SERGAS), As Xubias, 84 PC 15006, La Coruña, Spain. Manuel.Valladares.Ayerbes@sergas.es.|Translational Cancer Research Lab, Biomedical Research Institute (INIBIC), Carretera del Pasaje, s/n. PC 15006, La Coruña, Spain. Manuel.Valladares.Ayerbes@sergas.es.
authors.forename: Manuel
authors.initials: M
authors.lastname: Valladares-Ayerbes
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000401:mortality; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C533895:MIRN141 microRNA, human; C533896:MIRN200 microRNA, human; D035683:MicroRNAs